PubMed Health⌕ Search

Biomedical subjects

A Helander

Publications and source records attributed to A Helander.

At least 91 records · Page 5Linked to original sources

Topography and conformational preferences of 6,7,8,9-tetrahydro-1-hydroxy-N,N-dipropyl-5H-benzocyclohepten-6- ylamin e. A rationale for the dopaminergic inactivity.

In an attempt to rationalize the inability of phenolic benzocycloheptenylamines to activate dopamine (DA) D2 receptors, we have studied the conformational preferences and topography of 6,7,8,9-tetrahydro-1-hydroxy-N,N-dipropyl-5H-benzocyclohepten-6-++ +ylamine (1). Preferred conformations of 1 have been defined by use of experimental (NMR spectroscopic studies) and theoretical (MMP2, AM1, and MNDO calculations) methods. Topographical characteristics were studied by use of molecular graphics. Results from the MMP2 calculations agree with those from the AM1 calculations and the NMR spectroscopic study--1 seems to preferentially adopt chair conformations with a pseudoequatorial C6 substituent. The MNDO calculations, however, produced results that deviate considerably from those of the other theoretical methods. Most likely, pharmacophore conformations of (S)-1 do not present volumes that are part of the DA D2 receptor essential volume. Therefore, it appears that the energy penalty paid by the pharmacophore conformations is responsible for the dopaminergic inactivity of (S)-1. The inactivity of (R)-1 may be due to high energies of pharmacophore conformations and/or to steric factors since these conformations produce large excess volumes that may be part of the DA D2 receptor essential volume. The model used in the present report--a flexible pharmacophore combined with a partial receptor-excluded volume--might be used in the design of new DA D2 receptor agonists.

Benzocycloheptenes↗

(R)- and (S)-5,6,7,8-tetrahydro-1-hydroxy-N,N-dipropyl-9H-benzocyclohepten- 8-ylamine. Stereoselective interactions with 5-HT1A receptors in the brain.

The enantiomers of 5,6,7,8-tetrahydro-1-hydroxy-N,N-dipropyl-9H-benzocyclohepten-8-++ +ylamine (3) have been synthesized and evaluated for central 5-hydroxytryptamine (5-HT) and dopamine (DA) receptor activity by use of behavioral and biochemical tests in rats. In addition, the ability of the compounds to displace [3H]-8-OH-DPAT from 5-HT1A binding sites was evaluated. The absolute configuration of the enantiomers of 3 was determined indirectly by X-ray diffraction of (+)-(8R,alpha R)-5,6,7,8-tetrahydro-1-methoxy-N-(alpha-phenethyl)-9H- benzocyclohepten-8-ylamine hydrochloride (9.HCl), a resolved synthetic precursor. The stereoselectivity of the interaction of 3 with 5-HT1A receptors was more pronounced than that of 8-hydroxy-2-(dipropylamino)tetralin (1; 8-OH-DPAT); only (R)-3 displayed 5-HT activity. However, (R)-3 was of lower potency than any of the enantiomers of 1. The enantiomer (S)-3, which was found to be inactive as a 5-HT-receptor agonist, appeared to be a weakly potent DA-receptor agonist whereas (R)-3 seemed to be devoid of dopaminergic activity. The conformational preferences of 3 were studied by use of NMR spectroscopy and molecular mechanics calculations. Preferred conformations of (R)-3 are similar in shape to those of the stereoselective 5-HT1A-receptor agonist (2R,3S)-8-hydroxy-3-methyl-2-(dipropylamino)tetralin.

Animals↗

Effect of acute ethanol administration on human blood aldehyde dehydrogenase activity.

The aldehyde dehydrogenase (EC 1.2.1.3) activity in human blood was measured after acute oral administration of two different doses of ethanol to healthy subjects. No changes in aldehyde dehydrogenase activity were observed in either of the two dose groups, as compared to control subjects receiving no ethanol. Likewise, incubation of human whole blood samples with 20 mM ethanol for 2 hr caused no change in aldehyde dehydrogenase activity. The results show that human blood aldehyde dehydrogenase activity is not affected by acute ethanol administration.

Adult↗

Effects of disulfiram, cyanamide and 1-aminocyclopropanol on the aldehyde dehydrogenase activity in human erythrocytes and leukocytes.

The effects of the aldehyde dehydrogenase (ALDH; EC 1.2.1.3) inhibitors disulfiram, cyanamide and 1-aminocyclopropanol (ACP) on the ALDH activities in human erythrocytes and leukocytes were studied. Assays were performed by incubating intact or sonicated blood cells in the presence of different concentrations of the inhibitors, using 3,4-dihydroxyphenylacetaldehyde, the aldehyde derived from dopamine oxidation, as the substrate. The amount of acid metabolite formed was measured using high-performance liquid chromatography with electrochemical detection. The erythrocyte ALDH was extremely sensitive to disulfiram, and only about 0.5 microM was needed to cause a 50% inhibition of the activity. The leukocyte activity was less sensitive, and showed a similar degree of inhibition at an 100-fold higher concentration of disulfiram. Cyanamide and ACP were both potent inactivators of the leukocyte ALDH activity, giving a 50% inhibition at concentrations of 10 and 50 microM, respectively, whereas the erythrocyte activity was much less affected. Diethyldithiocarbamate, the reduced metabolite of disulfiram, and coprine, from which ACP is derived, were much less effective inhibitors of the erythrocyte and leukocyte ALDH activities than were disulfiram and ACP.

Aldehyde Dehydrogenase↗

Effects of ethanol, acetaldehyde and disulfiram on the metabolism of biogenic aldehydes in isolated human blood cells and platelets.

The effects of ethanol, acetaldehyde and disulfiram on the metabolism of biogenic aldehydes were measured in different human blood fractions. Intact erythrocytes, leukocytes and platelets were incubated in phosphate-buffered saline with 3,4-dihydroxyphenylacetaldehyde (DOPAL) or 5-hydroxy-indole-3-acetaldehyde (5-HIAL), the aldehydes derived from dopamine and serotonin, respectively. The disappearance of the aldehyde and the formation of acid and alcohol metabolites were analysed in the presence of different concentrations of ethanol, acetaldehyde or disulfiram using high-performance liquid chromatography with electrochemical detection. Ethanol at a concentration of 20 mM did not affect the biogenic aldehyde metabolism. High concentrations of acetaldehyde caused a dose-dependent inhibition of the disappearance rate of the biogenic aldehydes and of the formation rate of acid metabolites. In incubations with leukocytes or platelets, the inhibition of the acid formation was associated with a slight increase in the formation of the alcohol metabolites. Disulfiram at a concentration of 50 microM totally inhibited the metabolism of DOPAL and 5-HIAL in incubations with erythrocytes or platelets, whereas much less inhibition was observed in incubations with leukocytes.

3,4-Dihydroxyphenylacetic Acid↗

Metabolism of biogenic aldehydes in isolated human blood cells, platelets and in plasma.

The metabolism of biogenic aldehydes was measured in different human blood fractions. Isolated erythrocytes, leukocytes, platelets and plasma were incubated with 3,4-dihydroxyphenyl-acetaldehyde (DOPAL) or 5-hydroxyindole-3-acetaldehyde (5-HIAL), the aldehydes derived from dopamine and 5-hydroxytryptamine, respectively. The disappearance of the aldehydes and the formation of acid and alcohol metabolites were analysed using high-performance liquid chromatography with electrochemical detection. The aldehydes were unstable in phosphate-buffered saline, but this nonenzymatic oxidation was prevented in the presence of EDTA, pyrophosphate or blood tissue. When DOPAL or 5-HIAL were incubated with erythrocytes, only acid metabolites were formed, whereas both acid and alcohol metabolites were formed in incubations with leukocytes or platelets. The amount of the acid metabolite exceeded that of the alcohol metabolite, both with leukocytes and platelets. No metabolites were formed when the aldehydes were incubated in plasma. The oxidation of the aldehydes in incubations with erythrocytes or platelets was totally inhibited in the presence of 50 microM of the aldehyde dehydrogenase inhibitor disulfiram. However, disulfiram did not inhibit the metabolism of DOPAL and 5-HIAL in incubations with leukocytes, suggesting that different isozymes of aldehyde dehydrogenase are present in leukocytes as compared to erythrocytes and platelets.

3,4-Dihydroxyphenylacetic Acid↗

Metabolism of biogenic aldehydes in human blood: effects of ethanol, acetaldehyde and disulfiram.

The metabolism of biogenic aldehydes was measured in different fractions of human blood. Isolated erythrocytes, leukocytes, platelets and plasma were incubated with the aldehydes derived from dopamine and serotonin (DOPAL and 5-HIAL, respectively). The disappearance of the aldehydes and the formation of the acid and alcohol metabolites were analysed using HPLC with electrochemical detection. When erythrocytes were incubated with 1 microM DOPAL or 5-HIAL only the acid metabolites were formed, whereas both acid and alcohol metabolites were formed in incubations with leukocytes or platelets. No metabolites were formed when the aldehydes were incubated with plasma. In incubations with erythrocytes, the oxidation of the aldehydes was totally inhibited in the presence of 50 microM disulfiram, whereas the formation of both acid and alcohol metabolites was inhibited in incubations with platelets. Disulfiram did not affect the metabolism of DOPAL or 5-HIAL in incubations with leukocytes. The oxidation of the aldehydes was inhibited by 50-70% in the presence of a 500-fold excess of acetaldehyde. Ethanol at a concentration of 10 mM did not affect the metabolism.

3,4-Dihydroxyphenylacetic Acid↗

Aldehyde dehydrogenase activity and vascular disease in type II diabetes--a comparison between 2 different assays for activity.

We have recently reported that type II diabetic subjects with macroangiopathy have a higher activity of aldehyde dehydrogenase (ALDH) in blood than those without clinical vascular disease. ALDH activity was measured as the elimination of acetaldehyde added to a blood homogenate in vitro. We have re-examined our clinical material with another assay of ALDH which uses indole-3-acetaldehyde as substrate and measures the formation of indole-3-acetic acid. A negative correlation between the half-life of acetaldehyde and the formation of indole-3-acetic acid was found in the group of subjects free from vascular disease (r = -0.55, p less than 0.01). Thus, a rapid elimination of acetaldehyde corresponded to a rapid formation of indole-3-acetic acid. No such correlation was found in subjects with macroangiopathy. These results suggest that the 2 groups, with and without clinical vascular disease, have differences in isoenzyme composition, in the kinetic properties of the enzyme, or in the non-enzymatic binding of acetaldehyde.

Aldehyde Dehydrogenase↗

Kinetic and structural evidence for the identification of 11-hydroxythromboxane B2 dehydrogenase as cytosolic aldehyde dehydrogenase.

We have recently purified 11-hydroxythromboxane B2 dehydrogenase from porcine kidney and identified it as cytosolic aldehyde dehydrogenase (EC 1.2.1.3) based on amino acid analysis and other protein characteristics. In the present paper we have studied the catalytic interaction of thromboxane B2 (TXB2) with different aldehyde substrates and a potent aldehyde dehydrogenase inhibitor, disulfiram. TXB2 was a competitive inhibitor of the aldehyde dehydrogenase reaction in assays with 3,4-dihydroxyphenylacetaldehyde, a high affinity substrate. The conversion of TXB2 to 11-dehydro-TXB2 was also inhibited by propanal and disulfiram. The protein characteristics of the enzyme have also been further studied. The native enzyme is a tetramer and has an isoelectric point of 7.0 which is comparable with that of cytosolic aldehyde dehydrogenases from other species. Taken together the present data further indicate that 11-hydroxythromboxane B2 dehydrogenase is identical with cytosolic aldehyde dehydrogenase and that substrates and inhibitors of aldehyde dehydrogenase interact with thromboxane metabolism in vitro.

3,4-Dihydroxyphenylacetic Acid↗

Assay of human blood aldehyde dehydrogenase activity by high-performance liquid chromatography.

A simple and sensitive method for routine analysis of aldehyde dehydrogenase (ALDH, EC 1.2.1.3) activity in human blood has been developed. The assays were performed by incubating diluted whole blood samples in sodium pyrophosphate buffer in the presence of NAD. The aldehyde derived from dopamine, or alternatively the aldehyde from serotonin, was used as the substrate and the acid formed was measured using high-performance liquid chromatography with electrochemical detection. The present method can be performed with a small sample (10-25 microliters) of whole blood and no time-consuming pretreatments of the samples are needed. Six to seven samples can be assayed per hour, and the precision of the method was 2%. For comparison, assays were also performed with two fluorimetric methods, one measuring the formation of indole-3-acetic acid from indole-3-acetaldehyde and the other measuring the rate of acetaldehyde disappearance.

3,4-Dihydroxyphenylacetic Acid↗

Reactions of biogenic aldehydes with hemoglobin.

The aldehyde derivatives of dopamine and serotonin, 3,4-dihydroxyphenylacetaldehyde (DOPAL) and 5-hydroxyindole-3-acetaldehyde (5-HIAL), respectively, were incubated with human hemoglobin under physiological conditions. Both DOPAL and 5-HIAL, as well as dopamine, showed a time-dependent disappearance during the incubations, whereas this was not observed with serotonin. The amounts of free aldehydes recovered after incubation with hemoglobin, as analysed by high-performance liquid chromatography with electrochemical detection, corresponded to the amounts of acid metabolites formed in enzymatic assays, when the samples instead were incubated with aldehyde dehydrogenase. Incubations with DOPAL, 5-HIAL, or dopamine, and hemoglobin also resulted in distinct increases in the absorption spectra between 250-350 nm, whereas no similar increase was observed with serotonin. Addition of sodium borohydride to the incubates, which is used to stabilize Schiff base adducts between aldehydes and proteins, resulted in reduction of DOPAL and 5-HIAL to their corresponding alcohol metabolites. However, a rapid initial disappearance of the aldehydes, as analysed from the recoveries of the alcohol metabolites, was observed, followed by a more slow disappearance rate throughout the incubation period.

3,4-Dihydroxyphenylacetic Acid↗

Effects of benzodiazepines on aldehyde dehydrogenase activity.

The reported ability of benzodiazepines to increase human erythrocyte aldehyde dehydrogenase (ALDH) activity and reverse the disulfiram-induced inhibition of ALDH was reexamined. When ALDH activity assays were carried out spectrophotometrically on a hemoglobin-free lysate of human erythrocytes with propionaldehyde as substrate, addition of diazepam (10 mumol/l) did not affect the enzyme activity. When assays were carried out on intact or hemolysed erythrocytes using high performance liquid chromatographic technique with 3,4-dihydroxyphenylacetaldehyde as substrate, no significant increase in erythrocyte ALDH activity was found in the presence of chlordiazepoxide, oxazepam, diazepam, or desmethyldiazepam in the concentration range 1-20 mumol/l. Rather, a significant decrease (about 50%) in activity was obtained when lysed cells were incubated with 20 mumol/l chlordiazepoxide. Diazepam inhibited the rat liver mitochondrial low Km ALDH activity by about 50%. Disulfiram inhibited the ALDH activity almost completely in assays on human erythrocyte or rat liver mitochondrial ALDH. The ALDH activity was not regained by the subsequent addition of diazepam, nor was the effect of disulfiram reduced when diazepam was added prior to disulfiram. In an alcoholic subject who was followed during onset of disulfiram (Antabuse) therapy, the concurrent use of diazepam did not prevent a rapid decline in blood ALDH activity. The present results suggest that benzodiazepines do not increase ALDH activity in vitro, nor interfere with the inhibition of ALDH by disulfiram.

Adult↗

Study of Axis-Shield new %CDT immunoassay for quantification of carbohydrate-deficient transferrin (CDT) in serum.

Carbohydrate-deficient transferrin (CDT) in serum has emerged as a useful biochemical marker for identifying current alcohol misuse and monitoring abstinence. This study evaluated the performance of Axis-Shield new %CDT turbidimetric immunoassay (TIA; microtitre and Cobas Mira applications). Comparison was made with the previous Axis %CDT-TIA immunoassay (reference value <5.5%) and %CDT with the high-performance liquid chromatography (HPLC) technique (reference value <1.2%). The new %CDT assay measures primarily the asialo, monosialo and disialo transferrin isoforms, and the result is expressed as the amount relative to total transferrin. The analytical precision (coefficient of variation: CV) of the %CDT assay ranged between 3.1 and 8.5% for kit controls and serum samples. The %CDT values in serum from healthy social drinkers [i.e. Alcohol Use Disorders Identification Test (AUDIT) score 1-7 for men, and 1-5 for women] were 2.07 +/- 0.37% (mean +/- SD, range 1.4-3.3%, n = 100) and this was not significantly different from healthy non-drinkers (1.88 +/- 0.43%, 1.3-2.9%, n = 14), whereas abstinent alcohol patients showed slightly higher values (2.26 +/- 0.41, 1.7-3.4, n = 25). In chronic heavy drinkers (mean daily intake 225 +/- 137 g ethanol according to self-report), the %CDT values were markedly increased (6.33 +/- 4.01%, 1.2-18.0%, n = 107). There was no significant difference in %CDT values between male and female social drinkers. The reference value of the new %CDT assay to be used in clinical practice was tentatively set at <3.0%, which is slightly higher than that obtained by receiver operating characteristics (ROC) curve analysis (<2.8%) and that proposed by the manufacturer in the Instruction Manual (<2.6%). The %CDT assay showed good overall correlation with %CDT-TIA (r = 0.986, P < 0.0001) and %CDT-HPLC (r = 0.978, P < 0.0001). The specificity of the %CDT assay in healthy social drinkers was 98% (%CDT-TIA 100%, %CDT-HPLC 99%) and the sensitivity for any drinking during last week in the alcohol patients was 75% (%CDT-TIA 71%, %CDT-HPLC 80%). The new Axis-Shield %CDT assay can be recommended for routine use. However, whenever a positive immunoassay test result could lead to serious consequences for the individual, it is recommended to confirm the CDT result by the HPLC technique.

Adult↗

Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions.

The use of mushrooms containing the hallucinogenic substance psilocybin for intentional intoxication is relatively common. Occasionally, this results in adverse reactions with typical tachycardia that is not evidently caused by psilocybin. This study demonstrates the presence of phenylethylamine in the species Psilocybe semilanceata using gas chromatography-mass spectrometry and shows that the amount of this substance may vary much more than that of psilocybin. The highest amount of phenylethylamine (146 microg/g wet weight) was observed in mushrooms from a case of three young men hospitalized because of adverse reactions. Comparison of the symptoms observed in clinical cases of magic mushroom intoxication with those after intake of pure psilocybin or phenylethylamine suggests that phenylethylamine might have a role in the development of adverse reactions to Psilocybe mushroom intake.

Adult↗